#United States #Montreal #Congruence Therapeutics #CGX-926 #Genetic Obesity

Congruence Therapeutics Launches Phase 1/1b Clinical Trial for CGX-926

On March 19, 2026, Congruence Therapeutics marked a significant milestone in the battle against genetic obesity by announcing the dosing of its first participant in a Phase 1/1b clinical trial for CGX-926. This first-in-class oral small-molecule MC4R (melanocortin-4 receptor) corrector is designed to provide a new therapeutic approach for individuals suffering from obesity linked to mutations in the MC4R gene.

Understanding Genetic Obesity

Genetic obesity, primarily caused by mutations in the MC4R gene, remains the most common genetic form of obesity. Patients with such mutations often experience early-onset obesity and hyperphagia, leading to an insatiable appetite. With estimates suggesting that between 70,000 to 100,000 individuals in the United States are affected by pathogenic MC4R variants, CGX-926 aims to address an urgent medical need.

The MC4 receptor plays a crucial role in regulating appetite and metabolic homeostasis within the brain's leptin-melanocortin pathway. Given its significance in driving obesity related diseases, it has become a focal point for therapeutic development.

Trial Details

The Phase 1/1b clinical trial will focus on assessing the safety, tolerability, and pharmacokinetics of CGX-926 while preliminarily evaluating its efficacy in participants with MC4R-deficient obesity. As reported, preclinical studies demonstrated promising results during ObesityWeek 2025, indicating that CGX-926 could dose-dependently decrease weight and food intake in specific genetic mouse models. Notably, the treatment also facilitated weight loss without compromising lean muscle mass, a crucial factor for many patients.

Despite the availability of MC4R agonists like setmelanotide that have shown clinical benefits in patients with upstream ligand deficiencies, these therapies do not directly rectify defects in the MC4R receptor itself and are unsuitable for patients with MC4R mutations. CGX-926 aims to fill this therapeutic gap by targeting the receptor directly, presenting a tailored solution to a neglected patient population.

Expert Insight

Dr. Sadaf Farooqi, a renowned clinician scientist specializing in obesity genetics from the University of Cambridge, is leading the Phase 1b trial. Dr. Farooqi has a deep understanding of the genetic causes of obesity and emphasizes how critical this developmental step is for patients facing chronic hunger and obesity since childhood. She expressed optimism about the potential impact of CGX-926, stating, "This development offers real hope for people with this condition who suffer from persistent hunger and obesity from childhood."

Moreover, Congruence Therapeutics' Chief Development Officer, Michael D. Harvey, highlighted the importance of this trial as a key moment in their CGX-926 program. He noted, "This milestone showcases our Revenir™ platform's capability to generate therapies specifically targeting genetically confirmed drivers of disease."

Collaboration and Future Prospects

The trial is being conducted in collaboration with Quotient Sciences, utilizing their Translational Pharmaceutics® platform to assess CGX-926's safety and pharmacokinetics while evaluating early efficacy. Data from the Phase 1/1b study is anticipated to emerge in the first half of 2027, and both Congruence and its partners are enthusiastic about the implications this could have for managing genetic obesity more effectively.

The Revenir™ Platform

Revenir™, the proprietary drug discovery platform of Congruence Therapeutics, is designed to analyze proteins through their various functional states, providing unique insights into their behavior and potential modulation. By identifying allosteric and cryptic pockets within proteins, Revenir™ aids in discovering novel small molecule correctors. This strategic approach underlies Congruence's diverse drug pipeline targeting various genetic conditions, including both genetic obesity and other pressing medical needs such as GBA Parkinson's Disease.

As Congruence Therapeutics forges ahead with its clinical programs, the launch of the CGX-926 trial signifies a hopeful advancement in the treatment landscape for genetically driven obesity, addressing an area of urgent and unmet need in healthcare.